Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime Purchases 7,000 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 7,000 shares of the company’s stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the transaction, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, May 21st, Jean Jacques Bienaime acquired 2,000 shares of Immunome stock. The stock was acquired at an average cost of $13.57 per share, with a total value of $27,140.00.

Immunome Price Performance

IMNM traded up $0.77 on Monday, reaching $14.30. 322,115 shares of the stock were exchanged, compared to its average volume of 807,158. The company’s 50-day moving average price is $13.55 and its 200 day moving average price is $17.46. Immunome, Inc. has a fifty-two week low of $6.13 and a fifty-two week high of $30.96. The firm has a market capitalization of $857.56 million, a PE ratio of -1.89 and a beta of 1.78.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its position in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after acquiring an additional 918 shares during the period. Clear Creek Financial Management LLC raised its stake in shares of Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after buying an additional 4,035 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares in the last quarter. EntryPoint Capital LLC increased its stake in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Immunome in the 2nd quarter valued at about $81,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Ratings Changes

IMNM has been the subject of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Tuesday, August 13th. Piper Sandler lowered their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. initiated coverage on Immunome in a research report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has a consensus rating of “Buy” and an average price target of $29.00.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.